Platform processes have transformed biologics manufacturing.
They save development time, reduce uncertainty and allow CDMOs to build experience around repeatable workflows.
For many molecules, that is exactly what you want.
Then there are the proteins that refuse to cooperate.
Low expression. Inclusion bodies. Difficult folding. Unusual cofactors. Proteolysis. Aggregation. A purification step that works beautifully at 50 mL and badly at 50 L.
When the molecule stops behaving like the platform expects, selecting a protein manufacturing CDMO becomes a very different exercise.
The important question is what happens when the platform does not work
Most CDMOs can explain their standard workflow.
The more revealing conversation starts afterwards.
What happens if expression is poor? What if the protein is unstable after purification? Can the host be changed? Can the downstream strategy be redesigned? Is there enough development capability to investigate the mechanism rather than simply repeat the experiment?
For a straightforward molecule, rigid standardization can be an advantage.
For an unusual one, it may become a limitation.
This is why complex biologics need both infrastructure and scientific flexibility.
Difficult proteins rarely have one isolated problem
A common mistake is treating each manufacturing challenge independently.
Low recovery may appear to be a downstream issue. But the cause may begin upstream.
Expression conditions can influence folding, aggregation and impurity burden. Harvest timing can change proteolysis. Cell disruption conditions can expose the target protein to damaging environments. A buffer selected for purification performance may affect activity.
The complete process is connected.
A strong process development CDMO therefore looks across the workflow instead of optimizing individual unit operations in isolation.
Sometimes the correct solution to a purification problem is not another chromatography resin.
It is changing what happens several steps earlier.
Host flexibility matters more for unusual molecules
Standard host systems such as E. coli, Pichia pastoris, CHO and HEK cover a large proportion of recombinant protein production.
But they do not solve every biological problem equally well.
Secretion, folding, glycosylation, protease exposure and product localization differ substantially between systems.
A CDMO committed to only one proprietary platform may naturally try to solve the problem within that platform.
A more flexible model allows a different question:
Which system gives this particular molecule the best chance of becoming a robust manufacturing process?
That distinction is especially important before substantial development work becomes embedded in one host.
Ask about the science, not just the equipment
Capacity is easy to compare.
Scientific problem solving is harder.
When evaluating a CDMO for a challenging protein, discuss similar technical problems even if the molecules themselves were different.
Has the team worked with insoluble expression? Has it dealt with sensitive proteins, unusual purification behaviour or non standard hosts? How does it investigate low recovery? Can upstream, downstream and analytical teams review the same dataset together?
You are not looking for a guarantee that the CDMO has manufactured your exact molecule before.
For genuinely unusual proteins, that may be impossible.
You are looking for evidence that the team knows how to work when the answer is not already in the SOP.
Analytics become part of troubleshooting
Complex molecules also make analytical support more important.
You need to distinguish between losing protein and changing protein.
A lower apparent recovery may result from degradation, aggregation, precipitation or changes that alter the analytical response itself.
Without useful analytical feedback, process development can turn into trial and error.
Connecting analytics with development allows each experiment to answer a more useful question.
Not simply, “Did the yield increase?”
But, “What happened to the molecule and why?”
Flexibility still needs manufacturing discipline
A willingness to try new approaches does not mean development should remain open ended.
Eventually the process must become controllable and repeatable.
The role of development is to explore until the team understands enough to define a manufacturing strategy. As the project moves toward GMP, flexibility progressively becomes process control.
That transition is crucial.
A creative R&D solution that cannot be translated into reproducible biologics manufacturing has not solved the problem.
Find a CDMO that can adapt without losing direction
53Biologics’ positioning is deliberately built around programs that may require more than a fixed route.
The company supports recombinant proteins across microbial and mammalian expression systems, connecting strain or cell line decisions with process development, manufacturing, analytical support and fill finish. Its current protein offering includes microbial hosts such as E. coli, Pichia pastoris, Bacillus and filamentous fungi, alongside mammalian CHO and HEK programs.
The point is not to make a complex molecule sound simple.
It is to create a team and manufacturing path capable of working through that complexity without losing momentum.
If your protein does not fit neatly into a standard platform, that is not necessarily a reason to compromise the molecule.
It may simply mean you need a CDMO willing to shape the process around the science.
About 53Biologics:
53Biologics is the end-to-end biologics CDMO built to keep progress moving. We combine scientific expertise, integrated in-house capabilities and a close, hands-on way of working to help biotech teams make confident decisions, adapt as programs evolve and stay with one partner from early development through commercialization. With process development, manufacturing, analytics and fill-finish connected under one system, we reduce handoffs, protect continuity and help clients grow without disruption. We were made for this.
For more information or to speak with one of our experts email us at info@53biologics.com